
Hubbard et al, Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study



Hubbard et al, Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study




Figure S4: Distribution of vaccine-specific polyfunctional T cells

(A-B) Frequency of vaccine peptide-specific cytokine-producing CD8<sup>+</sup> (A) and CD4<sup>+</sup> (B) T-cells measured by *ex vivo* ICS assay for each patient before vaccination (PRE), and after 1 dose (week 3+6 pooled), after 2 doses (week 19), and after 3 doses (week 32). For stimulation pooled 9mers

Hubbard et al, Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study

(A) or pooled 30mers (B) were used. DMSO negative control was subtracted from all values. NT, not tested, NA, not applicable. (C) Distribution of vaccine-specific CD8<sup>+</sup> and CD4<sup>+</sup> T-cells upon stimulation with 9-mer peptides and 30-mer peptides measured by  $ex\ vivo$  intracellular cytokine staining (ICS) assay. Average distribution of vaccine peptide-specific polyfunctional CD8<sup>+</sup> (D) and CD4<sup>+</sup> (E) T-cell Responses detected before vaccination (PRE), after 1 (n=9), 2 (n=4), or 3 (n=4) vaccine doses as measured by  $ex\ vivo$  ICS assay. (F) Representative ( $ex\ vivo$ ) IFN- $\gamma$  – CD8 or CD4 ICS dot plots (one of three replicates) for patient 01-0005 before vaccination (PRE), and after 1 dose (week 3+6 pooled), after 2 doses (week 19), and after 3 doses (week 32) measured with pools of 9mers or 30mers and DMSO negative control.